Last reviewed · How we verify
Multiple intravenous doses of MRX-4 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Multiple intravenous doses of MRX-4 (Multiple intravenous doses of MRX-4) — MicuRx.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Multiple intravenous doses of MRX-4 TARGET | Multiple intravenous doses of MRX-4 | MicuRx | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Multiple intravenous doses of MRX-4 CI watch — RSS
- Multiple intravenous doses of MRX-4 CI watch — Atom
- Multiple intravenous doses of MRX-4 CI watch — JSON
- Multiple intravenous doses of MRX-4 alone — RSS
Cite this brief
Drug Landscape (2026). Multiple intravenous doses of MRX-4 — Competitive Intelligence Brief. https://druglandscape.com/ci/multiple-intravenous-doses-of-mrx-4. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab